A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Medical associations sue U.S. health leaders over COVID-19 vaccine restrictions, citing concerns about public health, vaccine ...

A shortened, all-oral drug regimen worked well for some patients with pre-extensively drug-resistant tuberculosis (pre-XDR TB ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

Health ministry has issued statement highlighting that extensive studies by ICMR and AIIMS, New Delhi have established there ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Six major medical groups, and a pregnant physician, are suing HHS Secretary Robert F. Kennedy Jr. over changes he made to ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...

Indian pharmaceutical industry leaders defend Covid-19 vaccines amid concerns, emphasizing safety, efficacy, and global ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...